Spondyloarthritis & psoriatic arthritis
Chronic kidney disease in patients with psoriatic arthritis: a cohort study
Authors' conclusion
CKD is not infrequent in PsA. Its development is associated with related comorbidities, joint damage and NSAID use. Methotrexate seems to be protective.
Study context
- Population
- Patients with psoriatic arthritis (PsA) followed by a prospective observational cohort; Chronic kidney disease (CKD) defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² for at least 3 months
- Participants
- 1,336 patients
- Outcome
- Prevalence of CKD
Methodological detailsprospective observational cohort, time-dependent Cox regression
- Prospective observational cohort
- Time-dependent Cox regression
Main finding
As reported in the abstract
CKD prevalence
CKD
123
9.2%
CKD at clinic entry (of CKD cases)
25
20.3%
Developed CKD during follow-up (of CKD cases)
98
79.7%
Observational data: associations, not effects.
Further findings
Time to CKD development from baseline
- Median (IQR) years
- 8.2 (2.8-14.0)
Long-term renal outcomes in new CKD cases
- Doubling of baseline creatinine
- 18 of 98 (18.3%)
- Sustained ≥40% reduction in baseline eGFR
- 49 (50%)
- eGFR <15 mL/min/1.73 m²
- 2
Factors independently associated with CKD development (multivariate Cox)
- Diabetes mellitus, HR
- 2.58, p<0.001
- Kidney stones, HR
- 2.14, p=0.01
- Radiographic damaged joint count, HR
- 1.02, p=0.02
- Uric acid (50-unit increase), HR
- 1.21, p<0.001
- Daily NSAID use, HR
- 1.77, p=0.02
- MTX use, HR
- 0.51, p=0.01
- Adjusted for age at study entry, sex and baseline eGFR
Original publication
Chronic kidney disease in patients with psoriatic arthritis: a cohort study. RMD Open. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →